• Tackle biomarker assay issues with Biomarin, Human Genome Sciences, and Genentech – bring back to your lab new approaches for including biomarkers in your PK/tox program, using biomarker assays as a trigger for treatment, and strategies to resolve heterophilic interference
• Half-day dedicated to all new Fc Functionality data
• Improve your developmental strategies for free and/or total antibody drug at the half-day workshop dedicated to case studies and open dialogue on the challenges, pros, and cons of developing free and total assays with Eli Lilly and Amgen
• Industry experts share strategies to generate meaningful data on molecular interactions to support biotherapeutic development
• Pfizer presents data on interference generated in different assay formats, using modeling as a predictive tool, and how to generate significant savings by reducing the number of assays requiring GLP validation.
Why IIR’s BAMD?
• Shorten development timelines to improve speed to market
• Network with colleagues to solve your biggest challenges
• Reduce costs by improving efficiencies in your lab
This is a unique opportunity to mingle with such an esteemed group of scientists all focusing on the advancement of bioanalytical method development! Register now and save $400 when mentioning code FVFVSBF.
|
Share this article with your social network, just click below to share now!
|
|
|
No comments :
Post a Comment